statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships

Immatics (IMTX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 27. Analyst Graig Suvannavejh fro...

Immatics (IMTX, $10.53) RSI Indicator left the oversold zone on March 28, 2024

This is a signal that IMTX's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Immatics N.V.'s (NASDAQ:IMTX) institutional investors lost 7.9% last week but have benefitted from longer-term gains

Key Insights Institutions' substantial holdings in Immatics implies that they have significant influence over the...

Immatics reports FY results

Immatics (NASDAQ:IMTX) Sees Large Volume Increase

Shares of Immatics (NASDAQ:IMTX  Get Free Report) saw an uptick in trading volume on Tuesday . 566,980 shares traded hands during trading, an increase of 14% from the previous sessions...

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Interim clinical data update on ACTengine IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median...

IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
IMTX stock results show that Immatics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of...

Immatics (IMTX, $12.07) price moved above its 50-day Moving Average on March 20, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

Immatics (IMTX, $12.08) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 7, 2024

This is a Bearish indicator signaling IMTX's price could decline from here. Traders may explore shorting the stock or put options...

Financial Comparison: Quantum Genomics Soci t  Anonyme (OTCMKTS:QNNTF) vs. Immatics (NASDAQ:IMTX)

Quantum Genomics Soci t Anonyme (OTCMKTS:QNNTF  Get Free Report) and Immatics (NASDAQ:IMTX  Get Free Report) are both small-cap medical companies, but which is the superior investment...

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.

Volume	308,289.00
52-Wk High	$13.77
52-Wk Low	$7.15

IMTX Immatics N.V

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community